CARDIOVASCULAR EVALUATION

This adverse event was reported 27 times

These drugs are most commonly taken by patients reporting CARDIOVASCULAR EVALUATION:

# Drug Count
0 RIVAROXABAN 4
1 ASPIRIN 3
2 ASPIRIN 325 MG 3
3 ASPIRIN 81 MG 3
4 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE 3
5 INTERFERON BETA-1A 3
6 MACITENTAN 3
7 AMLODIPINE BESYLATE 2
8 APIXABAN 2
9 RIOCIGUAT 2
See all common drugs associated with CARDIOVASCULAR EVALUATION

CARDIOVASCULAR EVALUATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LUMASIRAN 1 0.0026
1 VAMOROLONE 1 0.0006
2 IRBESARTAN AND HYDROCHLOROTHIAZIDE 1 0.0002
3 EPLERENONE 1 0.0001
4 EPOPROSTENOL 1 0.0001
5 MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE 1 0.0001
6 RIOCIGUAT 2 0.0001
7 INTERFERON BETA-1B 1 0.0001
8 ISOSORBIDE DINITRATE 1 0.0001
9 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE 3 0.0000
See all drugs enriched for association with CARDIOVASCULAR EVALUATION

CARDIOVASCULAR EVALUATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Soluble Guanylate Cyclase Stimulator [EPC] 2 0.0001
1 Integrin Receptor Antagonist [EPC] 3 0.0000
2 Rifamycin Antibacterial [EPC] 1 0.0000
3 Factor Xa Inhibitor [EPC] 7 0.0000
4 Folate Analog [EPC] 1 0.0000
5 Endothelin Receptor Antagonist [EPC] 4 0.0000
6 Vitamin A [EPC] 1 0.0000
7 Complement Inhibitor [EPC] 1 0.0000
8 Nicotinic Acid [EPC] 1 0.0000
9 Antidote [EPC] 1 0.0000
See all drug classes enriched for association with CARDIOVASCULAR EVALUATION